A detailed history of Wells Fargo & Company transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 160,228 shares of APLS stock, worth $6.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
160,228
Previous 145,035 10.48%
Holding current value
$6.03 Million
Previous $8.53 Million 27.91%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$38.07 - $59.71 $578,397 - $907,174
15,193 Added 10.48%
160,228 $6.15 Million
Q1 2024

May 10, 2024

BUY
$55.39 - $72.47 $690,602 - $903,555
12,468 Added 9.41%
145,035 $8.53 Million
Q4 2023

Feb 09, 2024

SELL
$37.14 - $64.82 $859,419 - $1.5 Million
-23,140 Reduced 14.86%
132,567 $7.94 Million
Q3 2023

Nov 13, 2023

BUY
$23.65 - $89.22 $1.5 Million - $5.67 Million
63,512 Added 68.89%
155,707 $5.92 Million
Q2 2023

Aug 15, 2023

SELL
$76.68 - $93.31 $1.03 Million - $1.25 Million
-13,423 Reduced 12.71%
92,195 $8.4 Million
Q1 2023

May 12, 2023

BUY
$46.59 - $66.96 $4.13 Million - $5.94 Million
88,673 Added 523.3%
105,618 $6.97 Million
Q4 2022

Feb 13, 2023

SELL
$43.24 - $61.04 $114,715 - $161,939
-2,653 Reduced 13.54%
16,945 $876,000
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $169,908 - $264,429
3,796 Added 24.02%
19,598 $1.34 Million
Q2 2022

Aug 12, 2022

SELL
$35.07 - $59.21 $898,388 - $1.52 Million
-25,617 Reduced 61.85%
15,802 $714,000
Q1 2022

May 16, 2022

SELL
$35.46 - $54.12 $798,062 - $1.22 Million
-22,506 Reduced 35.21%
41,419 $2.11 Million
Q4 2021

Feb 14, 2022

BUY
$30.74 - $49.16 $409,948 - $655,597
13,336 Added 26.36%
63,925 $3.02 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $451,846 - $1 Million
14,390 Added 39.75%
50,589 $1.67 Million
Q2 2021

Aug 16, 2021

BUY
$40.9 - $64.9 $1.07 Million - $1.7 Million
26,162 Added 260.66%
36,199 $2.29 Million
Q1 2021

May 13, 2021

SELL
$40.8 - $57.39 $1.57 Million - $2.2 Million
-38,386 Reduced 79.27%
10,037 $430,000
Q4 2020

Feb 09, 2021

BUY
$30.79 - $57.2 $676,117 - $1.26 Million
21,959 Added 82.98%
48,423 $2.77 Million
Q3 2020

Nov 05, 2020

SELL
$25.89 - $33.65 $365,981 - $475,676
-14,136 Reduced 34.82%
26,464 $799,000
Q2 2020

Aug 13, 2020

BUY
$24.8 - $38.49 $243,734 - $378,279
9,828 Added 31.94%
40,600 $1.33 Million
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $551,126 - $1.36 Million
30,772 New
30,772 $825,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.13B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.